HFS
FLNA

Hantz Financial Services’s Filana Therapeutics FLNA Stock Holding History

Hantz Financial Services’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
50
– – ﹤0.01% 2595
2025
Q4 		$0 Buy
+50
New +$160 ﹤0.01% 2523

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Hantz Financial Services's FLNA Position: Q1 2026 in Review

Hantz Financial Services held its Filana Therapeutics (FLNA) position steady in Q1 2026 at 50 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2595.

Hantz Financial Services first reported a position in FLNA in Q4 2025 and has held it in 2 quarters since. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • Hantz Financial Services held 50 shares of Filana Therapeutics worth $0 as of Q1 2026.
  • Hantz Financial Services left its Filana Therapeutics share count unchanged in Q1 2026.
  • Filana Therapeutics made up ﹤0.01% of Hantz Financial Services's portfolio in Q1 2026, its #2595 holding.
  • Hantz Financial Services first reported a position in Filana Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on Hantz Financial Services's 13F filing for Q1 2026, filed 1 May 2026.